China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2018
October 2018
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and seniorexecutives of China National Accord Medicines Corporation Ltd. (hereinafterreferred to as the Company) hereby confirm that there are no any fictitiousstatements, misleading statements, or important omissions carried in this report,and shall take all responsibilities, individual and/or joint, for the reality, accuracyand completion of the whole contents.All directors are present the meeting of the Board for deliberating the ThirdQuarter Report of the Company in person.Lin Zhaoxiong, person in charge of the Company, head of the accounting worksWei Pingxiao and Wang Ying, accounting body principals (accountant in charge)hereby confirm that the Financial Report of the Third Quarterly Report isauthentic, accurate and complete.
Section II. Basic information of Company
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□ Yes √ No
| Current period-end | Period-end of last year | Increase/decrease | ||||
| Total assets (RMB) | 28,244,710,026.77 | 22,343,643,527.77 | 26.41% | |||
| Net assets attributable to shareholders of listed company (RMB) | 11,016,212,543.22 | 9,396,572,345.88 | 17.24% | |||
| Current period | Increase/decrease in comparison with same period of last year | Year-begin to end of the Period | Increase/decrease in comparison with year-begin to period-end of last year | |||
| Operating revenue (RMB) | 10,987,540,368.77 | 2.17% | 31,766,707,068.44 | 1.56% | ||
| Net profit attributable to shareholders of the listed company (RMB) | 285,244,535.54 | 15.49% | 926,971,570.47 | 15.42% | ||
| Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses (RMB) | 282,319,350.57 | 15.27% | 905,615,689.91 | 14.46% | ||
| Net cash flow arising from operating activities (RMB) | -- | -- | 563,991,295.36 | 10.35% | ||
| Basic earnings per share (RMB/Share) | 0.666 | 15.42% | 2.165 | 15.41% | ||
| Diluted earnings per share (RMB/Share) | 0.666 | 15.42% | 2.165 | 15.41% | ||
| Weighted average ROE | 2.62% | 0.13 percent down | 9.21% | 0.06 percent up | ||
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
| Item | Amount from year-begin to end of the Period | Note |
| Gains/losses from the disposal of non-current asset (including the write-off that accrued for impairment of assets) | 4,361,450.64 | Account of property expropriation received in the |
| period from government | ||
| Governmental subsidy reckoned into current gains/losses (not including the subsidy enjoyed in quota or ration according to national standards, which are closely relevant to enterprise’s business) | 14,437,530.16 | Received vary specific subsidy and financial discount in the period |
| Income from the exceeding part between investment cost of the Company paid for obtaining subsidiaries, associates and joint-ventures and recognizable net assets fair value attributable to the Company when acquiring the investment | 729.29 | Income from subsidiary- Sinopharm Holding Guangzhou Huadu Co., Ltd. acquisition in the period |
| Reversal of impairment reserve for account receivable with separate impairment testing | 4,292,235.76 | Net gain/loss of impairment provision switch-back for receivables |
| Gains/losses on entrusted loans | 2,398,288.34 | Income for providing entrust loans to China National Zhijun (Suzhou) |
| Other non-operating income and expenditure except for the aforementioned items | 2,843,762.60 | |
| Less: impact on income tax | 6,376,396.25 | |
| Impact on minority shareholders’ equity (post-tax) | 601,719.98 | |
| Total | 21,355,880.56 | -- |
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for CompaniesOffering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according tothe lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering TheirSecurities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists ofextraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to thePublic --- Extraordinary Profit/loss.
II. Statement of the total shareholders and shares-held of top ten shareholders at end of thePeriod
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
| Total common shareholders at the end of report period | 18,993 | Total preference shareholders with voting rights recovered at end of reporting period (if applicable) | 0 | ||||
| Top ten shareholders | |||||||
| Shareholders | Nature of | Proportion of | Amount of shares | Amount of | Number of share pledged/frozen | ||
| shareholder | shares held | held | restricted shares held | State of share | Amount | |
| Sinopharm Group Co., Ltd. | State-owned corporate | 56.06% | 239,999,991 | 55,057,700 | ||
| HTHK/CMG FSGUFP-CMG FIRST STATE CHINA GROWTH FD | Overseas corporate | 2.37% | 10,141,182 | |||
| China Life Insurance Co., Ltd. – tradition –general insurance products -005L-CT001 Shen | Domestic non state-owned corporate | 1.97% | 8,415,792 | |||
| China Insurance – traditional insurance products | Domestic non state-owned corporate | 1.42% | 6,092,905 | |||
| China National Pharmaceutical Foreign Trade Corp. | State-owned corporate | 1.24% | 5,323,043 | 5,323,043 | ||
| National Social Security Fund -103 | Domestic non state-owned corporate | 1.17% | 4,999,987 | |||
| GUOTAI JUNAN SECURITIES(HONGKONG) LIMITED | Overseas corporate | 1.03% | 4,396,898 | |||
| New China Life Insurance Company Ltd. －Dividend －individual bonuses -018L-FH002 Shen | Domestic non state-owned corporate | 0.98% | 4,199,772 | |||
| #Beijing Hao Qing Wealth Investment Management Co., | Domestic non state-owned corporate | 0.96% | 4,118,716 |
| Ltd. –Hao Qing Value Stable No.8 Investment Fund | ||||||
| UBS AG LONDON BRANCH | Overseas corporate | 0.90% | 3,833,984 | |||
| Particular about top ten shareholders with un-restrict shares held | ||||||
| Shareholders | Amount of un-restrict shares held | Type of shares | ||||
| Type | Amount | |||||
| Sinopharm Group Co., Ltd. | 184,942,291 | RMB ordinary shares | 184,942,291 | |||
| HTHK/CMG FSGUFP-CMG FIRST STATE CHINA GROWTH FD | 10,141,182 | Domestically listed foreign shares | 10,141,182 | |||
| China Life Insurance Co., Ltd. – tradition –general insurance products -005L-CT001 Shen | 8,415,792 | RMB ordinary shares | 8,415,792 | |||
| China Insurance – traditional insurance products | 6,092,905 | RMB ordinary shares | 6,092,905 | |||
| National Social Security Fund -103 | 4,999,987 | RMB ordinary shares | 4,999,987 | |||
| GUOTAI JUNAN SECURITIES(HONGKONG) LIMITED | 4,396,898 | Domestically listed foreign shares | 4,396,898 | |||
| New China Life Insurance Company Ltd. －Dividend －individual bonuses -018L-FH002 Shen | 4,199,772 | RMB ordinary shares | 4,199,772 | |||
| # Beijing Hao Qing Wealth Investment Management Co., Ltd. –Hao Qing Value Stable No.8 Investment Fund | 4,118,716 | RMB ordinary shares | 4,118,716 | |||
| UBS AG LONDON BRANCH | 3,833,984 | Domestically listed foreign shares | 3,833,984 | |||
| China SAFE Investments Limited | 3,804,400 | RMB ordinary shares | 3,804,400 | |||
| Explanation on associated relationship among the aforesaid shareholders | Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information | |||||
| Disclosure on Change of Shareholding for Listed Companies. | |
| Explanation on top ten common shareholders involving margin business (if applicable) | Beijing Hao Qing Wealth Investment Management Co., Ltd. –Hao Qing Value Stable No.8 Investment Fund holds 4,048,216 shares of the Company through margin trading and refinancing secured security account |
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement dealingin reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
Section III. Important events
I. Particular about major changes from items of main accounting statements and financialindexes as well as reasons
√ Applicable □Not applicable
1. Cash and bank balances: increased 2,792 million Yuan over that of year -begin with growth rate of 66.60%, mainly because thesubsidiary Guoda Drugstore received strategic capital injection from strategic investor;2. Note receivable: decreased 629 million Yuan over that of year -begin with growth rate of -41.85%, mainly because note returndeclined in the period;3. Account receivable: increased 2,861 million Yuan over that of year -begin with growth rate of 37.70%, mainly because the businessdevelopment and more business increased as well as the repayment period increased;4. Other current assets: decreased 28.7738 million Yuan over that of year-begin with growth rate of -36.45%, mainly because morenon-deductible input tax occurred for large quantity of purchase at end of the year;5. Total current assets: increased 5,684 million Yuan over that of year-begin with growth rate of 31.03%, mainly because the subsidiaryGuoda Drugstore received strategic capital injection from strategic investor;6. Other equity instrument investment: increased 1,400 million Yuan over that of year-begin with growth rate of 1,022.96%, mainlybecause invested medical industry fund in the period;7. Construction in progress: increased 16.6964 million Yuan over that of year-begin with growth rate of 72.76%, mainly due to theconstruction charge of ERP system;8. Other non-current assets: decreased 68.7461 million Yuan over that of year-begin with growth rate of -48.41%, mainly due to theapplication of new financial instruments standards, the medical industry fund was re-classified as other equity instrument investment;9. Short-term loans: increased 626 million Yuan over that of year-begin with growth rate of 40.08%, mainly because the supply chainfinance increased;10. Other current liability: increased 46,800 Yuan over that of year-begin with growth rate of 41.48%, mainly because the amount ofsales tax to be sold increased over that of year-begin;11. Long-term account payable: decreased 3.9437 million Yuan over that of year-begin with growth rate of -42.26%, mainly becausethe finance lease rent is paid in the period;12. Non-controlling equity: increased 2,005 million Yuan over that of year-begin with growth rate of 377.68%, mainly becausesubsidiary Guoda Drugstore received a capital-increase from strategy investor in the period;
13. Total owner’s equity: increased 3,625 million Yuan over that of year-begin with growth rate of 36.51%, mainly because subsidiary
Guoda Drugstore received a capital-increase from strategy investor in the period;14. Assets impairment loss: decreased 1.8963 million Yuan over that of year-begin with growth rate of -123.65%, mainly because the
previous year’s receivables with special accrual for bad debts has collected in the period;
15. Income from assets disposal: increased 4.3521 million Yuan on a y-o-y basis with growth rate of 78,509.59%, mainly becausereceived an account of property expropriation from government in the period;16. Non-operation expenditure: decreased 6.1545 million Yuan on a y-o-y basis with growth rate of -73.92%, mainly because thepenalty and reimbursement occurred in the period declined from a year earlier;17. Gains/loss of minority shareholders: increased 20.1132 million Yuan on a y-o-y basis with growth rate of 31.74%, mainly becausesubsidiary Guoda Drugstore introduced strategic investor in the period, thus the gains/loss of minority shareholders increasedcorrespondingly;18. Total comprehensive income attributable to minority shareholders: increased 20.1132 million Yuan on a y-o-y basis with growth
rate of 31.74%, mainly because subsidiary Guoda Drugstore introduced strategic investor in the period, thus the total comprehensiveincome attributable to minority shareholders increased correspondingly;19. Write-back of tax received: decreased 5.8595 million Yuan on a y-o-y basis with growth rate of -77.36%, mainly because thereceived write-back of tax has decreased in the period;20. Cash received with other operation activities concerned: increased 281 million Yuan on a y-o-y basis with growth rate of 126.76%,mainly because the quality and performance bond received in the period increased on a y-o-y basis;21. Cash received from investment income: increased 70.7961 million Yuan on a y-o-y basis with growth rate of 117.67%, mainlybecause the interest received on entrusted loans from associated enterprise increased on a y-o-y basis in the period;22. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: increased 5.1661 million Yuan on ay-o-y basis with growth rate of 882.31%, mainly because the revenue from intangible assets disposal increased on a y-o-y basis;23. Subtotal of cash in-flow from investment activity: increased 77.9619 million Yuan on a y-o-y basis with growth rate of 48.72%,mainly because the interest received on entrusted loans from associated enterprise increased on a y-o-y basis in the period;24. Net cash paid for acquiring subsidiary and other operation units: decreased 18.525 million Yuan on a y-o-y basis with growth rateof -100.00%, mainly because the equity amount are paid for subsidiary acquisition last period while no such amount occurred in theperiod;25. Other cash paid concerning investing activities: decreased 58.0525 million Yuan on a y-o-y basis with growth rate of -42.07%,mainly because the bill deposits have decreased in the period;26. Net cash flow from investment activity: increased 136 million Yuan on a y-o-y basis with growth rate of 62.28%, mainly becausethe interest received on entrusted loans from associated enterprise increased on a y-o-y basis in the period;27. Cash received from absorption of investment: increased 2,778 million Yuan on a y-o-y basis with growth rate of 25,385.25%,mainly because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;28. Cash received from borrowing: decreased 247 million Yuan on a y-o-y basis with growth rate of -83.24%, mainly because themobile loans received from the bank declined on a y-o-y basis;29. Subtotal of cash in-flow from financing activity: increased 2,537 million Yuan on a y-o-y basis with growth rate of 618.25%,mainly because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;30. Cash paid for debts: decreased 210 million Yuan on a y-o-y basis with growth rate of -72.54%, mainly because the cash paid fordebts declined on a y-o-y basis for change of the bank deposit in the period;31. Cash paid with other financing activity concerned: decreased 127 million Yuan on a y-o-y basis with growth rate of -67.67%,mainly because the factoring commission and interest on financial leasing paid in the period declined on a y-o-y basis;32. Subtotal of cash out-flow from financing activity: decreased 316 million Yuan on a y-o-y basis with growth rate of -43.11%,mainly because the cash paid for debts declined on a y-o-y basis for change of the bank deposit in the period;33. Net cash flow from financing activity: increased 2,853 million Yuan on a y-o-y basis with growth rate of 884.55%, mainly becausesubsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;34. Influence on cash and cash equivalent caused by fluctuations in exchange: decreased 314,500 Yuan on a y-o-y basis with growthrate of -100.00%, mainly caused by the exchange rate conversion for dividend payout of B-share in HK dollar;35. Net increase of cash and cash equivalent: increased 3,042 million Yuan on a y-o-y basis with growth rate of 10,257.11%, mainlybecause subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period;36. Balance of cash and cash equivalent at period-end: increased 3,564 million Yuan on a y-o-y basis with growth rate of 114.19%,
mainly because subsidiary Guoda Drugstore received strategic capital injection from strategy investor in the period.
II. Progress and influence of the main events as well as solution analysis specification
□ Applicable √ Not applicable
III. Commitments that the company, shareholders, actual controller, offeror, directors,supervisors, senior management or other related parties have fulfilled during the reportingperiod and have not yet fulfilled by the end of reporting period
□ Applicable √ Not applicable
There are no commitments that the company, shareholders, actual controller, offeror, directors, supervisors, senior management or otherrelated parties have fulfilled during the reporting period and have not yet fulfilled by the end of reporting period.
IV. Estimation of operation performance for year of 2018
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the warningof its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
V. Particular about security investment
□ Applicable √ Not applicable
The Company had no security investment in Period.
VI. Trust financing
□ Applicable √ Not applicable
The Company had no trust financing in Period.
VII. Particulars about derivatives investment
□ Applicable √ Not applicable
The Company had no derivatives investment in Period.
VIII. Registration form of receiving research, communication and interview in the reportperiod
□Applicable √ Not applicable
The Company has no research, communication and interview accepted in the Period.
IX. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the reporting period.
X. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation from controlling shareholders and its related party.
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2018-09-30
In RMB
| Item | Balance at period-end | Balance at period-begin |
| Current assets: | ||
| Cash and bank balances | 6,983,234,857.70 | 4,191,655,438.51 |
| Settlement provisions | ||
| Capital lent | ||
| Transactional financial assets | ||
| Derivative financial assets | ||
| Notes receivable and accounts receivable | 11,325,059,730.25 | 9,093,607,443.96 |
| Including: Notes receivable | 874,740,558.07 | 1,504,194,764.08 |
| Accounts receivable | 10,450,319,172.18 | 7,589,412,679.88 |
| Advances to suppliers | 463,638,268.60 | 516,778,117.47 |
| Insurance receivable | ||
| Reinsurance receivables | ||
| Contract reserve of reinsurance receivable | ||
| Other receivables | 543,343,748.58 | 657,932,499.65 |
| Purchase restituted finance asset | ||
| Inventories | 4,639,692,765.59 | 3,781,858,238.12 |
| Contractual assets | ||
| Assets held for sale | ||
| Non-current asset due within one year | ||
| Other current assets | 50,173,873.93 | 78,947,644.62 |
| Total current assets | 24,005,143,244.65 | 18,320,779,382.33 |
| Non-current assets: | ||
| Loans and payments on behalf |
| Investment in creditor’s rights | ||
| Other investment in creditor’s rights | ||
| Long-term account receivable | ||
| Long-term equity investment | 1,782,914,509.18 | 1,650,619,373.09 |
| Other equity instruments investment | 153,685,760.00 | 13,685,760.00 |
| Other non current financial assets | ||
| Investment property | 143,416,634.53 | 153,678,339.11 |
| Fixed assets | 556,542,495.67 | 551,710,434.02 |
| Construction in progress | 39,643,659.20 | 22,947,258.99 |
| Productive biological asset | ||
| Oil and gas asset | ||
| Intangible assets | 310,687,053.16 | 325,751,430.88 |
| Expense on Research and Development | ||
| Goodwill | 830,729,152.75 | 830,729,152.75 |
| Long-term prepaid expenses | 266,030,743.26 | 252,247,050.79 |
| Deferred income tax asset | 82,640,420.15 | 79,472,883.06 |
| Other non-current asset | 73,276,354.22 | 142,022,462.75 |
| Total non-current asset | 4,239,566,782.12 | 4,022,864,145.44 |
| Total assets | 28,244,710,026.77 | 22,343,643,527.77 |
| Current liabilities: | ||
| Short-term loans | 2,187,210,613.46 | 1,561,354,521.64 |
| Loan from central bank | ||
| Absorbing deposit and interbank deposit | ||
| Capital borrowed | ||
| Transactional financial liabilities | ||
| Derivative financial liability | ||
| Notes payable and accounts payable | 10,511,611,711.71 | 8,876,658,828.52 |
| Advances from customers | 184,636,672.94 | 216,938,239.32 |
| Contract liabilities | ||
| Selling financial asset of repurchase | ||
| Commission charge and commission payable | ||
| Payable to employee | 192,940,541.14 | 215,656,526.54 |
| Taxes payable | 194,484,692.28 | 223,752,900.24 |
| Other accounts payable | 1,136,010,493.24 | 1,030,329,660.02 |
| Reinsurance payables | ||
| Insurance contract reserve | ||
| Security trading of agency | ||
| Security sales of agency | ||
| Liability held for sale | ||
| Non-current liabilities due within 1 year | 5,755,080.19 | 5,434,770.70 |
| Other current liabilities | 159,609.75 | 112,817.65 |
| Total current liabilities | 14,412,809,414.71 | 12,130,238,264.63 |
| Non-current liabilities: | ||
| Long-term loans | 31,600,000.00 | 31,600,000.00 |
| Bonds payable | ||
| Including: preferred stock | ||
| Perpetual capital securities | ||
| Long-term account payable | 5,388,881.21 | 9,332,537.14 |
| Long-term Payable to employee | 1,636,000.00 | 1,777,000.00 |
| Projected liabilities | ||
| Deferred income | 122,453,251.86 | 125,082,372.53 |
| Deferred income tax liabilities | 72,212,487.72 | 71,883,253.02 |
| Other non-current liabilities | 46,227,343.31 | 46,227,343.31 |
| Total non-current liabilities | 279,517,964.10 | 285,902,506.00 |
| Total liabilities | 14,692,327,378.81 | 12,416,140,770.63 |
| Owner’s equity: | ||
| Share capital | 428,126,983.00 | 428,126,983.00 |
| Other equity instrument | ||
| Including: preferred stock | ||
| Perpetual capital securities | ||
| Capital surplus | 4,002,535,786.76 | 3,181,429,064.99 |
| Less: Inventory shares | ||
| Other comprehensive income | ||
| Reasonable reserve | ||
| Surplus reserve | 214,063,491.50 | 214,063,491.50 |
| Provision of general risk | ||
| Retained earnings | 6,371,486,281.96 | 5,572,952,806.39 |
| Shareholders’ equity attributable to shareholders of parent company | 11,016,212,543.22 | 9,396,572,345.88 |
| Non-controlling interests | 2,536,170,104.74 | 530,930,411.26 |
| Total owner’s equity | 13,552,382,647.96 | 9,927,502,757.14 |
| Total liabilities and owner’s equity | 28,244,710,026.77 | 22,343,643,527.77 |
Legal representative: Lin ZhaoxiongPerson in charge of accounting works: Wei PingxiaoPerson in charge of accounting institution: Wang Ying
2. Balance Sheet of Parent Company
In RMB
| Item | Balance at period-end | Balance at period-begin |
| Current assets: | ||
| Cash and bank balances | 1,644,584,431.40 | 1,776,696,342.87 |
| Transactional financial assets | ||
| Derivative financial assets | ||
| Notes receivable and accounts receivable | 707,800,384.53 | 545,267,378.99 |
| Including: Notes receivable | 16,596,621.54 | 64,799,618.07 |
| Accounts receivable | 691,203,762.99 | 480,467,760.92 |
| Advances to suppliers | 2,213,378.98 | 1,138,312.26 |
| Other receivables | 1,403,855,929.94 | 1,517,882,239.81 |
| Inventories | 179,871,213.92 | 172,022,676.96 |
| Contractual assets | ||
| Assets held for sale | ||
| Non-current assets maturing within one year | ||
| Other current assets | 39,482.38 | 788,964.90 |
| Total current assets | 3,938,364,821.15 | 4,013,795,915.79 |
| Non-current assets: | ||
| Investment in creditor’s rights | ||
| Other investment in creditor’s rights | ||
| Long-term receivables | ||
| Long-term equity investments | 7,329,323,360.05 | 7,180,306,084.56 |
| Other equity instruments investment | 140,000,000.00 | |
| Other non-current financial assets | ||
| Investment property | 2,157,848.81 | 2,763,831.92 |
| Fixed assets | 20,156,870.46 | 13,831,103.54 |
| Construction in progress | ||
| Productive biological assets | ||
| Oil and natural gas assets | ||
| Intangible assets | 1,497,529.30 | 1,287,775.78 |
| Research and development costs | ||
| Goodwill | ||
| Long-term prepaid expenses | 4,726,014.47 | 5,543,217.86 |
| Deferred income tax assets | 3,248,549.21 | 2,764,724.75 |
| Other non-current assets | 7,000,000.00 | 71,808,611.00 |
| Total non-current assets | 7,508,110,172.30 | 7,278,305,349.41 |
| Total assets | 11,446,474,993.45 | 11,292,101,265.20 |
| Current liabilities: | ||
| Short-term loans | 664,000,000.00 | 707,000,000.00 |
| Transactional financial liabilities | ||
| Derivative financial liability | ||
| Notes payable and accounts payable | 714,750,735.49 | 674,450,646.65 |
| Advances from customers | 984,581.64 | 1,912,503.90 |
| Contract liabilities | ||
| Payable to employee | 28,883,832.34 | 33,592,851.93 |
| Taxes payable | 7,469,386.55 | 42,386,907.00 |
| Other accounts payable | 1,081,738,486.24 | 1,415,723,188.96 |
| Liability held for sale | ||
| Non-current liabilities due within 1 year | ||
| Other current liabilities | 159,609.75 | 112,817.65 |
| Total current liabilities | 2,497,986,632.01 | 2,875,178,916.09 |
| Non-current liabilities: | ||
| Long-term loans | 31,600,000.00 | 31,600,000.00 |
| Bonds payable | ||
| Including: preferred stock | ||
| Perpetual capital securities | ||
| Long-term account payable | 800,000.00 | 800,000.00 |
| Long-term Payable to employee |
| Projected liabilities | ||
| Deferred income | 1,756,431.56 | 2,054,250.00 |
| Deferred income tax liabilities | 4,749,282.38 | 3,773,319.00 |
| Other non-current liabilities | ||
| Total non-current liabilities | 38,905,713.94 | 38,227,569.00 |
| Total liabilities | 2,536,892,345.95 | 2,913,406,485.09 |
| Owners’ equity: | ||
| Share capital | 428,126,983.00 | 428,126,983.00 |
| Other equity instrument | ||
| Including: preferred stock | ||
| Perpetual capital securities | ||
| Capital surplus | 4,407,519,808.63 | 4,407,091,484.13 |
| Less: Inventory shares | ||
| Other comprehensive income | ||
| Reasonable reserve | ||
| Surplus reserve | 214,063,491.50 | 214,063,491.50 |
| Retained earnings | 3,859,872,364.37 | 3,329,412,821.48 |
| Total owner’s equity | 8,909,582,647.50 | 8,378,694,780.11 |
| Total liabilities and owner’s equity | 11,446,474,993.45 | 11,292,101,265.20 |
3. Consolidated Profit Statement (the period)
In RMB
| Item | Current Period | Last Period |
| I. Total operating income | 10,987,540,368.77 | 10,753,911,112.98 |
| Including: Operating income | 10,987,540,368.77 | 10,753,911,112.98 |
| Interest income | ||
| Insurance gained | ||
| Commission charge and commission income | ||
| II. Total operating cost | 10,672,350,613.96 | 10,476,330,643.94 |
| Including: Operating cost | 9,749,853,630.20 | 9,652,629,532.14 |
| Interest expense | ||
| Commission charge and commission expense |
| Cash surrender value | ||
| Net amount of expense of compensation | ||
| Net amount of withdrawal of insurance contract reserve | ||
| Bonus expense of guarantee slip | ||
| Reinsurance expense | ||
| Taxes and surcharges | 30,175,966.21 | 27,755,633.18 |
| Sales expenses | 682,736,449.56 | 576,266,856.55 |
| Administration expenses | 188,693,332.32 | 183,065,386.00 |
| R&D expenses | ||
| Financial expenses | 20,736,052.88 | 35,176,387.62 |
| Including: Interest expenses | 45,676,535.07 | 40,724,369.96 |
| Interest income | 26,253,068.71 | 8,547,239.22 |
| Losses of devaluation of asset | 155,182.79 | 1,436,848.45 |
| Credit impairment loss | ||
| Add: other income | 1,815,373.95 | 4,885,408.95 |
| Investment income (Loss is listed with “-”) | 78,983,284.46 | 54,961,155.07 |
| Including: Investment income on affiliated company and joint venture | 78,933,284.46 | 54,961,155.07 |
| Net exposure hedging benefits (Loss is listed with “-”) | ||
| Changing income of fair value(Loss is listed with “-”) | ||
| Exchange income (Loss is listed with “-”) | ||
| Income from assets disposal (Loss is listed with “-”) | 76,479.50 | -479,542.26 |
| III. Operating profit (Loss is listed with “-”) | 396,064,892.72 | 336,947,490.80 |
| Add: Non-operating income | 1,553,611.12 | 3,013,969.77 |
| Less: Non-operating expense | 374,027.37 | 4,765,878.32 |
| IV. Total Profit (Loss is listed with “-”) | 397,244,476.47 | 335,195,582.25 |
| Less: Income tax expense | 76,038,019.79 | 68,255,324.72 |
| V. Net profit (Net loss is listed with “-”) | 321,206,456.68 | 266,940,257.53 |
| (i) net profit from continuous operation (Net loss is listed with “-”) | 321,206,456.68 | 266,940,257.53 |
| (ii) net profit from discontinued operation (Net loss is listed with “-”) | ||
| Net profit attributable to owner’s of parent company | 285,244,535.54 | 246,977,990.75 |
| Minority shareholders’ gains and losses | 35,961,921.14 | 19,962,266.78 |
| VI. Net after-tax of other comprehensive income | ||
| Net after-tax of other comprehensive income attributable to owners of parent company | ||
| (I) Other comprehensive income items which will not be reclassified subsequently to profit of loss | ||
| 1. Changes as a result of re-measurement of net defined benefit plan liability or asset | ||
| 2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit and loss | ||
| 3. Change of the fair value of other equity instrument investment | ||
| 4.Change of the fair value of enterprise’s own credit risk | ||
| 5. Other | ||
| (II) Other comprehensive income items which will be reclassified subsequently to profit or loss | ||
| 1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss | ||
| 2. Change of fair value of other debt investment |
| 3.Amount of financial assets re-classified to other comprehensive income | ||
| 4.Credit impairment provision for other debt investment | ||
| 5.Cash flow hedging reserve | ||
| 6. Translation differences arising on translation of foreign currency financial statements | ||
| 7. Other | ||
| Net after-tax of other comprehensive income attributable to minority shareholders | ||
| VII. Total comprehensive income | 321,206,456.68 | 266,940,257.53 |
| Total comprehensive income attributable to owners of parent Company | 285,244,535.54 | 246,977,990.75 |
| Total comprehensive income attributable to minority shareholders | 35,961,921.14 | 19,962,266.78 |
| VIII. Earnings per share: | ||
| (i) Basic earnings per share | 0.666 | 0.577 |
| (ii) Diluted earnings per share | 0.666 | 0.577 |
As for the business merger under the same control in the Period, 0 Yuan net profit realized before merger by thecombined party, the net profit for combined party in last period was 0 Yuan.Legal representative: Lin ZhaoxiongPerson in charge of accounting works: Wei PingxiaoPerson in charge of accounting institution: Wang Ying
4. Profit Statement of Parent Company (the period)
In RMB
| Item | Current Period | Last Period |
| I. Operating income | 899,859,002.45 | 900,080,112.15 |
| Less: Operating cost | 856,296,603.88 | 869,401,788.37 |
| Taxes and surcharges | 1,445,734.44 | 784,481.12 |
| Sales expenses | 16,953,141.79 | 12,874,352.60 |
| Administration expenses | 16,785,749.55 | 16,582,316.33 |
| R&D expenses |
| Financial expenses | -10,270,272.65 | -6,369,097.36 |
| Including: Interest expenses | 10,951,050.33 | 5,184,109.36 |
| Interest income | 21,345,942.02 | 11,829,749.52 |
| Losses of devaluation of asset | -152,059.06 | 117,780.84 |
| Credit impairment loss | ||
| Add: other income | 121,990.82 | |
| Investment income (Loss is listed with “-”) | 84,991,405.06 | 63,018,807.05 |
| Including: Investment income on affiliated company and joint venture | 84,991,405.06 | 60,919,200.32 |
| Net exposure hedging benefits (Loss is listed with “-”) | ||
| Changing income of fair value(Loss is listed with “-”) | ||
| Income from assets disposal (Loss is listed with “-”) | 11,116.50 | |
| II. Operating profit (Loss is listed with “-”) | 103,924,616.88 | 69,707,297.30 |
| Add: Non-operating income | 3.98 | 3,387.55 |
| Less: Non-operating expense | 850,000.01 | |
| III. Total Profit (Loss is listed with “-”) | 103,924,620.86 | 68,860,684.84 |
| Less: Income tax expense | 4,806,491.84 | 1,455,763.24 |
| IV. Net profit (Net loss is listed with “-”) | 99,118,129.02 | 67,404,921.60 |
| (i) net profit from continuous operation (Net loss is listed with “-”) | 99,118,129.02 | 67,404,921.60 |
| (ii) net profit from discontinued operation (Net loss is listed with “-”) | ||
| V. Net after-tax of other comprehensive income | ||
| (I) Other comprehensive income items which will not be reclassified subsequently to profit of loss | ||
| 1. Changes as a result of re-measurement of net defined benefit plan liability or asset | ||
| 2. Share of the other |
| comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit and loss | ||
| 3. Change of the fair value of other equity instrument investment | ||
| 4.Change of the fair value of enterprise’s own credit risk | ||
| 5. Other | ||
| (II) Other comprehensive income items which will be reclassified subsequently to profit or loss | ||
| 1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss | ||
| 2. Change of fair value of other debt investment | ||
| 3.Amount of financial assets re-classified to other comprehensive income | ||
| 4.Credit impairment provision for other debt investment | ||
| 5.Cash flow hedging reserve | ||
| 6. Translation differences arising on translation of foreign currency financial statements | ||
| 7. Other | ||
| VI. Total comprehensive income | 99,118,129.02 | 67,404,921.60 |
| VII. Earnings per share: | ||
| (i) Basic earnings per share | ||
| (ii) Diluted earnings per share |
5. Consolidated Profit Statement (form the year-begin to the period-end)
In RMB
| Item | Current Period | Last Period |
| I. Total operating income | 31,766,707,068.44 | 31,278,718,782.55 |
| Including: Operating income | 31,766,707,068.44 | 31,278,718,782.55 |
| Interest income | ||
| Insurance gained | ||
| Commission charge and commission income | ||
| II. Total operating cost | 30,779,047,376.24 | 30,399,229,240.83 |
| Including: Operating cost | 28,117,497,354.04 | 28,016,663,982.97 |
| Interest expense | ||
| Commission charge and commission expense | ||
| Cash surrender value | ||
| Net amount of expense of compensation | ||
| Net amount of withdrawal of insurance contract reserve | ||
| Bonus expense of guarantee slip | ||
| Reinsurance expense | ||
| Taxes and surcharges | 86,796,493.46 | 90,941,254.04 |
| Sales expenses | 1,956,325,205.63 | 1,686,713,794.72 |
| Administration expenses | 540,513,396.10 | 523,701,437.11 |
| R&D expenses | ||
| Financial expenses | 78,277,597.20 | 79,675,166.38 |
| Including: Interest expenses | 129,032,902.25 | 100,292,883.44 |
| Interest income | 49,335,302.27 | 26,007,610.64 |
| Losses of devaluation of asset | -362,670.19 | 1,533,605.61 |
| Credit impairment loss | ||
| Add: other income | 12,404,586.52 | 12,843,902.62 |
| Investment income (Loss is listed with “-”) | 241,677,055.81 | 201,687,194.97 |
| Including: Investment income on affiliated company and joint venture | 241,595,555.81 | 201,637,194.97 |
| Net exposure hedging benefits (Loss is listed with “-”) | ||
| Changing income of fair value(Loss is listed with “-”) | ||
| Exchange income (Loss is listed |
| with “-”) | ||
| Income from assets disposal (Loss is listed with “-”) | 4,357,644.11 | 5,543.40 |
| III. Operating profit (Loss is listed with “-”) | 1,246,098,978.64 | 1,094,026,182.71 |
| Add: Non-operating income | 7,052,562.23 | 9,070,112.60 |
| Less: Non-operating expense | 2,171,320.17 | 8,325,866.41 |
| IV. Total Profit (Loss is listed with “-”) | 1,250,980,220.70 | 1,094,770,428.90 |
| Less: Income tax expense | 240,524,754.11 | 228,296,432.35 |
| V. Net profit (Net loss is listed with “-”) | 1,010,455,466.59 | 866,473,996.55 |
| (i) net profit from continuous operation (Net loss is listed with “-”) | 1,010,455,466.59 | 866,473,996.55 |
| (ii) net profit from discontinued operation (Net loss is listed with “-”) | ||
| Net profit attributable to owner’s of parent company | 926,971,570.47 | 803,103,308.94 |
| Minority shareholders’ gains and losses | 83,483,896.12 | 63,370,687.61 |
| VI. Net after-tax of other comprehensive income | ||
| Net after-tax of other comprehensive income attributable to owners of parent company | ||
| (I) Other comprehensive income items which will not be reclassified subsequently to profit of loss | ||
| 1. Changes as a result of re-measurement of net defined benefit plan liability or asset | ||
| 2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit and loss | ||
| 3. Change of the fair value of other equity instrument investment | ||
| 4.Change of the fair value of enterprise’s own credit risk |
| 5. Other | ||
| (II) Other comprehensive income items which will be reclassified subsequently to profit or loss | ||
| 1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss | ||
| 2. Change of fair value of other debt investment | ||
| 3.Amount of financial assets re-classified to other comprehensive income | ||
| 4.Credit impairment provision for other debt investment | ||
| 5.Cash flow hedging reserve | ||
| 6. Translation differences arising on translation of foreign currency financial statements | ||
| 7. Other | ||
| Net after-tax of other comprehensive income attributable to minority shareholders | ||
| VII. Total comprehensive income | 1,010,455,466.59 | 866,473,996.55 |
| Total comprehensive income attributable to owners of parent Company | 926,971,570.47 | 803,103,308.94 |
| Total comprehensive income attributable to minority shareholders | 83,483,896.12 | 63,370,687.61 |
| VIII. Earnings per share: | ||
| (i) Basic earnings per share | 2.165 | 1.876 |
| (ii) Diluted earnings per share | 2.165 | 1.876 |
As for the business merger under the same control in the Period, 0 Yuan net profit realized before merger by thecombined party, the net profit for combined party in last period was 0 Yuan.
6. Profit Statement of Parent Company (form the year-begin to the period-end)
In RMB
| Item | Current Period | Last Period |
| I. Operating income | 2,587,480,358.28 | 2,558,680,931.11 |
| Less: Operating cost | 2,471,014,077.79 | 2,470,049,377.83 |
| Taxes and surcharges | 3,462,103.37 | 5,846,798.28 |
| Sales expenses | 42,847,937.24 | 35,718,966.89 |
| Administration expenses | 50,464,856.30 | 41,500,304.54 |
| R&D expenses | ||
| Financial expenses | -29,640,152.73 | -43,412,064.91 |
| Including: Interest expenses | 31,721,163.76 | 10,323,519.88 |
| Interest income | 62,271,142.76 | 54,307,313.03 |
| Losses of devaluation of asset | 471,483.25 | 85,176.13 |
| Credit impairment loss | ||
| Add: other income | 1,421,335.96 | 641,300.00 |
| Investment income (Loss is listed with “-”) | 619,832,149.52 | 571,379,548.90 |
| Including: Investment income on affiliated company and joint venture | 258,317,695.20 | 216,757,940.77 |
| Net exposure hedging benefits (Loss is listed with “-”) | ||
| Changing income of fair value(Loss is listed with “-”) | ||
| Income from assets disposal (Loss is listed with “-”) | 11,116.50 | 1,087.38 |
| II. Operating profit (Loss is listed with “-”) | 670,124,655.04 | 620,914,308.63 |
| Add: Non-operating income | 37.06 | 187,919.51 |
| Less: Non-operating expense | 127,688.63 | 1,861,760.16 |
| III. Total Profit (Loss is listed with “-”) | 669,997,003.47 | 619,240,467.98 |
| Less: Income tax expense | 11,099,365.68 | 23,311,778.81 |
| IV. Net profit (Net loss is listed with “-”) | 658,897,637.79 | 595,928,689.17 |
| (i) net profit from continuous operation (Net loss is listed with “-”) | 658,897,637.79 | 595,928,689.17 |
| (ii) net profit from discontinued operation (Net loss is listed with “-”) |
| V. Net after-tax of other comprehensive income | ||
| (I) Other comprehensive income items which will not be reclassified subsequently to profit of loss | ||
| 1. Changes as a result of re-measurement of net defined benefit plan liability or asset | ||
| 2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit and loss | ||
| 3. Change of the fair value of other equity instrument investment | ||
| 4. Change of the fair value of enterprise’s own credit risk | ||
| 5. Other | ||
| (II) Other comprehensive income items which will be reclassified subsequently to profit or loss | ||
| 1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss | ||
| 2. Change of fair value of other debt investment | ||
| 3. Amount of financial assets re-classified to other comprehensive income | ||
| 4. Credit impairment provision for other debt investment | ||
| 5. Cash flow hedging reserve | ||
| 6. Translation differences arising on translation of foreign currency financial statements | ||
| 7. Other | ||
| VI. Total comprehensive income | 658,897,637.79 | 595,928,689.17 |
| VII. Earnings per share: | ||
| (i) Basic earnings per share | ||
| (ii) Diluted earnings per share |
7. Consolidated Cash Flow Statement (form the year-begin to the period-end)
In RMB
| Item | Current Period | Last Period |
| I. Cash flows arising from operating activities: | ||
| Cash received from selling commodities and providing labor services | 33,576,126,717.79 | 33,680,871,791.23 |
| Net increase of customer deposit and interbank deposit | ||
| Net increase of loan from central bank | ||
| Net increase of capital borrowed from other financial institution | ||
| Cash received from original insurance contract fee | ||
| Net cash received from reinsurance business | ||
| Net increase of insured savings and investment | ||
| Net increase of amount from disposal financial assets that measured by fair value and with variation reckoned into current gains/losses | ||
| Cash received from interest, commission charge and commission | ||
| Net increase of capital borrowed | ||
| Net increase of returned business capital | ||
| Write-back of tax received | 1,714,760.21 | 7,574,262.64 |
| Other cash received concerning operating activities | 503,409,429.80 | 222,004,857.99 |
| Subtotal of cash inflow arising from operating activities | 34,081,250,907.80 | 33,910,450,911.86 |
| Cash paid for purchasing commodities and receiving labor service | 30,058,268,141.08 | 30,272,872,617.59 |
| Net increase of customer loans and advances | ||
| Net increase of deposits in central bank and interbank | ||
| Cash paid for original insurance contract compensation | ||
| Cash paid for interest, commission charge and commission | ||
| Cash paid for bonus of guarantee slip | ||
| Cash paid to/for staff and workers | 1,392,220,211.12 | 1,266,243,435.50 |
| Taxes paid | 818,864,295.31 | 861,250,651.49 |
| Other cash paid concerning operating activities | 1,247,906,964.93 | 999,000,769.40 |
| Subtotal of cash outflow arising from operating activities | 33,517,259,612.44 | 33,399,367,473.98 |
| Net cash flows arising from operating activities | 563,991,295.36 | 511,083,437.88 |
| II. Cash flows arising from investing activities: | ||
| Cash received from recovering investment | ||
| Cash received from investment income | 130,963,345.37 | 60,167,262.76 |
| Net cash received from disposal of fixed, intangible and other long-term assets | 5,751,674.16 | 585,524.78 |
| Net cash received from disposal of subsidiaries and other units | ||
| Other cash received concerning investing activities | 101,261,607.73 | 99,261,955.41 |
| Subtotal of cash inflow from investing activities | 237,976,627.26 | 160,014,742.95 |
| Cash paid for purchasing fixed, intangible and other long-term assets | 150,353,192.93 | 126,571,984.56 |
| Cash paid for investment | 90,000,000.00 | 95,137,145.33 |
| Net increase of mortgaged loans | ||
| Net cash received from subsidiaries and other units obtained | 18,525,000.00 | |
| Other cash paid concerning investing activities | 79,921,476.82 | 137,974,010.61 |
| Subtotal of cash outflow from investing activities | 320,274,669.75 | 378,208,140.50 |
| Net cash flows arising from investing activities | -82,298,042.49 | -218,193,397.55 |
| III. Cash flows arising from financing activities | ||
| Cash received from absorbing investment | 2,788,851,200.00 | 10,943,000.00 |
| Including: Cash received from absorbing minority shareholders’ investment by subsidiaries | 2,788,851,200.00 | 10,943,000.00 |
| Cash received from loans | 49,670,200.30 | 296,311,793.77 |
| Cash received from issuing bonds | ||
| Other cash received concerning financing activities | 108,949,307.54 | 103,113,564.29 |
| Subtotal of cash inflow from financing activities | 2,947,470,707.84 | 410,368,358.06 |
| Cash paid for settling debts | 79,670,200.30 | 290,130,072.33 |
| Cash paid for dividend and profit distributing or interest paying | 276,628,059.98 | 255,153,017.01 |
| Including: Dividend and profit of minority shareholder paid by subsidiaries | 56,858,945.30 | 36,992,199.01 |
| Other cash paid concerning financing activities | 60,658,096.82 | 187,628,354.86 |
| Subtotal of cash outflow from financing activities | 416,956,357.10 | 732,911,444.20 |
| Net cash flows arising from financing activities | 2,530,514,350.74 | -322,543,086.14 |
| IV. Influence on cash and cash equivalents due to fluctuation in exchange rate | -314,517.97 | |
| V. Net increase of cash and cash | 3,011,893,085.64 | -29,653,045.81 |
| equivalents | ||
| Add: Balance of cash and cash equivalents at the period -begin | 3,673,498,691.48 | 3,150,909,425.54 |
| VI. Balance of cash and cash equivalents at the period -end | 6,685,391,777.12 | 3,121,256,379.73 |
8. Cash Flow Statement of Parent Company (form the year-begin to the period-end)
In RMB
| Item | Current Period | Last Period |
| I. Cash flows arising from operating activities: | ||
| Cash received from selling commodities and providing labor services | 2,681,236,630.70 | 2,597,564,040.32 |
| Write-back of tax received | ||
| Other cash received concerning operating activities | 91,958,196.80 | 26,424,030.63 |
| Subtotal of cash inflow arising from operating activities | 2,773,194,827.50 | 2,623,988,070.95 |
| Cash paid for purchasing commodities and receiving labor service | 2,559,377,589.52 | 2,572,754,403.03 |
| Cash paid to/for staff and workers | 61,913,310.95 | 56,647,266.92 |
| Taxes paid | 29,801,808.96 | 39,084,840.35 |
| Other cash paid concerning operating activities | 45,140,599.54 | 25,300,370.50 |
| Subtotal of cash outflow arising from operating activities | 2,696,233,308.97 | 2,693,786,880.80 |
| Net cash flows arising from operating activities | 76,961,518.53 | -69,798,809.85 |
| II. Cash flows arising from investing activities: | ||
| Cash received from recovering investment | ||
| Cash received from investment income | 255,904,643.39 | 216,058,026.83 |
| Net cash received from disposal of fixed, intangible and other long-term | 35,200.00 |
| assets | ||
| Net cash received from disposal of subsidiaries and other units | ||
| Other cash received concerning investing activities | 1,218,035,586.01 | 2,156,269,200.00 |
| Subtotal of cash inflow from investing activities | 1,473,975,429.40 | 2,372,327,226.83 |
| Cash paid for purchasing fixed, intangible and other long-term assets | 8,607,026.77 | 6,871,001.07 |
| Cash paid for investment | 90,000,000.00 | 1,045,900,000.00 |
| Net cash received from subsidiaries and other units | 18,525,000.00 | |
| Other cash paid concerning investing activities | 1,267,321,606.82 | 1,691,189,918.90 |
| Subtotal of cash outflow from investing activities | 1,365,928,633.59 | 2,762,485,919.97 |
| Net cash flows arising from investing activities | 108,046,795.81 | -390,158,693.14 |
| III. Cash flows arising from financing activities | ||
| Cash received from absorbing investment | ||
| Cash received from loans | 10,000,000.00 | 41,600,000.00 |
| Cash received from issuing bonds | ||
| Other cash received concerning financing activities | 12,559,913,378.52 | 11,644,239,507.12 |
| Subtotal of cash inflow from financing activities | 12,569,913,378.52 | 11,685,839,507.12 |
| Cash paid for settling debts | 10,000,000.00 | 41,600,000.00 |
| Cash paid for dividend and profit distributing or interest paying | 153,116,428.79 | 146,079,007.62 |
| Other cash paid concerning financing activities | 12,723,602,657.57 | 11,231,111,506.09 |
| Subtotal of cash outflow from financing activities | 12,886,719,086.36 | 11,418,790,513.71 |
| Net cash flows arising from financing activities | -316,805,707.84 | 267,048,993.41 |
| IV. Influence on cash and cash | -314,517.97 |
| equivalents due to fluctuation in exchange rate | ||
| V. Net increase of cash and cash equivalents | -132,111,911.47 | -192,908,509.58 |
| Add: Balance of cash and cash equivalents at the period -begin | 1,776,696,342.87 | 1,342,041,409.86 |
| VI. Balance of cash and cash equivalents at the period -end | 1,644,584,431.40 | 1,149,132,900.28 |
II. Audit report
Whether the 3
rd
quarterly report has been audited or not
□Yes √ No
The 3
rd
quarterly report of the Company has not been audited.